Table of Contents Author Guidelines Submit a Manuscript
Journal of Diabetes Research
Volume 2015, Article ID 162718, 9 pages
http://dx.doi.org/10.1155/2015/162718
Research Article

Determining Predictors of Early Response to Exenatide in Patients with Type 2 Diabetes Mellitus

Department of Diabetes & Endocrinology, Countess of Chester Hospital NHS Foundation Trust, Chester CH2 1UL, UK

Received 14 September 2014; Revised 24 December 2014; Accepted 25 December 2014

Academic Editor: Daisuke Koya

Copyright © 2015 Muhammad Khan et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. R. H. Unger and A. M. Eisentraut, “Entero-insular axis,” Archives of Internal Medicine, vol. 123, no. 3, pp. 261–266, 1969. View at Publisher · View at Google Scholar · View at Scopus
  2. W. Creutzfeldt, “The incretin concept today,” Diabetologia, vol. 16, no. 2, pp. 75–85, 1979. View at Publisher · View at Google Scholar · View at Scopus
  3. M. A. Nauck, N. Kleine, C. Orskov, J. J. Holst, B. Willms, and W. Creutzfeldt, “Normalization of fasting hyperglycaemia by exogenous glucagon-like peptide 1 (7–36 amide) in Type 2 (non-insulin-dependent) diabetic patients,” Diabetologia, vol. 36, no. 8, pp. 741–744, 1993. View at Publisher · View at Google Scholar · View at Scopus
  4. M. Zander, S. Madsbad, J. L. Madsen, and J. J. Holst, “Effect of 6-week course of glucagon-like peptide 1 on glycaemic control, insulin sensitivity, and β-cell function in type 2 diabetes: a parallel-group study,” The Lancet, vol. 359, no. 9309, pp. 824–830, 2002. View at Publisher · View at Google Scholar · View at Scopus
  5. V. R. Aroda, R. R. Henry, J. Han et al., “Efficacy of GLP-1 receptor agonists and DPP-4 inhibitors: meta-analysis and systematic review,” Clinical Therapeutics, vol. 34, no. 6, pp. 1247.e22–1258.e22, 2012. View at Publisher · View at Google Scholar · View at Scopus
  6. T. Vilsbøll, M. Christensen, A. E. Junker, F. K. Knop, and L. L. Gluud, “Effects of glucagon-like peptide-1 receptor agonists on weight loss: systematic review and meta-analyses of randomised controlled trials,” British Medical Journal, vol. 344, no. 7841, Article ID d7771, 2012. View at Publisher · View at Google Scholar · View at Scopus
  7. J. Buteau, “GLP-1 receptor signaling: effects on pancreatic β-cell proliferation and survival,” Diabetes and Metabolism, vol. 34, supplement 2, pp. S73–S77, 2008. View at Publisher · View at Google Scholar · View at Scopus
  8. M. Shimoda, Y. Kanda, S. Hamamoto et al., “The human glucagon-like peptide-1 analogue liraglutide preserves pancreatic beta cells via regulation of cell kinetics and suppression of oxidative and endoplasmic reticulum stress in a mouse model of diabetes,” Diabetologia, vol. 54, no. 5, pp. 1098–1108, 2011. View at Publisher · View at Google Scholar · View at Scopus
  9. T. Vilsbøll, “The effects of glucagon-like peptide-1 on the beta cell,” Diabetes, Obesity and Metabolism, vol. 11, no. 3, pp. 11–18, 2009. View at Publisher · View at Google Scholar · View at Scopus
  10. “Type 2 diabetes: new agents for blood glucose control in type 2 diabetes,” 2014, https://www.nice.org.uk/guidance/ta203/resources/guidance-liraglutide-for-the-treatment-of-type-2-diabetes-mellitus-pdf.
  11. “Liraglutide for the treatment of type 2 diabetes mellitus,” http://www.nice.org.uk/advice/esnm26/resources/non-guidance-type-2-diabetes-lixisenatide-pdf.
  12. “ESNM26: Type 2 diabetes: lixisenatide,” http://publications.nice.org.uk/esnm26type-2-diabetes-lixisenatide-esnm26.
  13. “Exenatide prolonged-release suspension for injection in combination with oral antidiabetic therapy for the treatment of type 2 diabetes,” February 2014, http://www.nice.org.uk/nicemedia/live/13670/58205/58205.pdf.
  14. R. A. DeFronzo, R. E. Ratner, J. Han, D. D. Kim, M. S. Fineman, and A. D. Baron, “Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2,” Diabetes Care, vol. 28, no. 5, pp. 1092–1100, 2005. View at Publisher · View at Google Scholar · View at Scopus
  15. D. M. Kendall, M. C. Riddle, J. Rosenstock et al., “Effects of exenatide (exendin-4) on glycemic control over 30 weeks in patients with type 2 diabetes treated with metformin and a sulfonylurea,” Diabetes Care, vol. 28, no. 5, pp. 1083–1091, 2005. View at Publisher · View at Google Scholar · View at Scopus
  16. R. J. Heine, L. F. Van Gaal, D. Johns, M. J. Mihm, M. H. Widel, and R. G. Brodows, “Exenatide versus insulin glargine in patients with suboptimally controlled type 2 diabetes: a randomized trial,” Annals of Internal Medicine, vol. 143, no. 8, pp. 559–I30, 2005. View at Publisher · View at Google Scholar · View at Scopus
  17. M. J. Davies, R. Donnelly, A. H. Barnett, S. Jones, C. Nicolay, and A. Kilcoyne, “Exenatide compared with long-acting insulin to achieve glycaemic control with minimal weight gain in patients with type 2 diabetes: results of the helping evaluate exenatide in patients with diabetes compared with long-acting insulin (HEELA) study,” Diabetes, Obesity & Metabolism, vol. 11, no. 12, pp. 1153–1162, 2009. View at Publisher · View at Google Scholar · View at Scopus
  18. M. Nauck, A. Frid, K. Hermansen et al., “Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin, in type 2 diabetes,” Diabetes Care, vol. 32, no. 1, pp. 84–90, 2009. View at Publisher · View at Google Scholar · View at Scopus
  19. J. B. Buse, D. J. Drucker, K. L. Taylor et al., “DURATION-1: exenatide once weekly produces sustained glycemic control and weight loss over 52 weeks,” Diabetes Care, vol. 33, no. 6, pp. 1255–1261, 2010. View at Publisher · View at Google Scholar · View at Scopus
  20. M. Pinget, R. Goldenberg, E. Niemoeller, I. Muehlen-Bartmer, H. Guo, and R. Aronson, “Efficacy and safety of lixisenatide once daily versus placebo in type 2 diabetes insufficiently controlled on pioglitazone (GetGoal-P),” Diabetes, Obesity and Metabolism, vol. 15, no. 11, pp. 1000–1007, 2013. View at Publisher · View at Google Scholar · View at Scopus
  21. B. Ahrén, A. L. Dimas, P. Miossec, S. Saubadu, and R. Aronson, “Efficacy and safety of lixisenatide once-daily morning or evening injections in type 2 diabetes inadequately controlled on metformin (GetGoal-M),” Diabetes Care, vol. 36, no. 9, pp. 2543–2550, 2013. View at Publisher · View at Google Scholar · View at Scopus
  22. J. Rosenstock, D. Raccah, L. Koranyi et al., “Efficacy and safety of lixisenatide once daily versus exenatide twice daily in type2diabetes inadequately controlled on metformin: a 24-week, randomized, open-label, active-controlled study (GetGoal-X),” Diabetes Care, vol. 36, no. 10, pp. 2945–2951, 2013. View at Publisher · View at Google Scholar · View at Scopus
  23. B. Zinman, J. Gerich, J. B. Buse et al., “Efficacy and safety of the human glucagon-like peptide-1 analog liraglutide in combination with metformin and thiazolidinedione in patients with type 2 diabetes (LEAD-4 Met+TZD),” Diabetes Care, vol. 32, no. 7, pp. 1224–1230, 2009. View at Publisher · View at Google Scholar · View at Scopus
  24. J. B. Buse, J. Rosenstock, G. Sesti et al., “Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6),” The Lancet, vol. 374, no. 9683, pp. 39–47, 2009. View at Publisher · View at Google Scholar · View at Scopus
  25. R. Turner, “Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group,” The Lancet, vol. 352, no. 9131, pp. 837–853, 1998. View at Publisher · View at Google Scholar · View at Scopus
  26. S. L. Anderson, J. M. Trujillo, M. McDermott, and J. J. Saseen, “Determining predictors of response to exenatide in type 2 diabetes,” Journal of the American Pharmacists Association, vol. 52, no. 4, pp. 466–471, 2012. View at Publisher · View at Google Scholar · View at Scopus
  27. V. Preumont, M. P. Hermans, M. Bergman, and M. Buysschaert, “Predictive factors associated with primary failure to exenatide and non goal attainment in patients with type 2 diabetes,” Acta Clinica Belgica, vol. 67, no. 6, pp. 411–415, 2012. View at Publisher · View at Google Scholar · View at Scopus
  28. J. Kozawa, K. Inoue, R. Iwamoto et al., “Liraglutide is effective in type 2 diabetic patients with sustained endogenous insulin-secreting capacity,” Journal of Diabetes Investigation, vol. 3, no. 3, pp. 294–297, 2012. View at Publisher · View at Google Scholar · View at Scopus
  29. R. Anichini, S. Cosimi, A. di Carlo et al., “Gender difference in response predictors after 1-year exenatide therapy twice daily in type 2 diabetic patients: a real world experience,” Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy, vol. 6, pp. 123–129, 2013. View at Publisher · View at Google Scholar · View at Scopus
  30. S. O. Song, K. J. Kim, B.-W. Lee, E. S. Kang, B. S. Cha, and H. C. Lee, “Tolerability, effectiveness and predictive parameters for the therapeutic usefulness of exenatide in obese, Korean patients with type 2 diabetes,” Journal of Diabetes Investigation, vol. 5, no. 5, pp. 554–562, 2014. View at Publisher · View at Google Scholar · View at Scopus
  31. J. Shin, J.-S. Chang, H.-S. Kim et al., “Effects of a 6-month exenatide therapy on hba1c and weight in Korean patients with type 2 diabetes: a retrospective cohort study,” Diabetes and Metabolism Journal, vol. 36, no. 5, pp. 364–370, 2012. View at Publisher · View at Google Scholar · View at Scopus
  32. D. Simon, “Therapeutic inertia in type 2 diabetes: insights from the PANORAMA study in France,” Diabetes & Metabolism, vol. 38, supplement 3, pp. S47–S52, 2012. View at Publisher · View at Google Scholar · View at Scopus